<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Guerbet Sa — News on 6ix</title>
    <link>https://6ix.com/company/guerbet-sa</link>
    <description>Latest news and press releases for Guerbet Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 22 May 2026 16:14:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/guerbet-sa" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d531f3beedb30cb6f6d8b2.webp</url>
      <title>Guerbet Sa</title>
      <link>https://6ix.com/company/guerbet-sa</link>
    </image>
    <item>
      <title>Guerbet: Changes to the Composition of Guerbet’s Board of Directors.</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-changes-to-the-composition-of-guerbets-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-changes-to-the-composition-of-guerbets-board-of-directors</guid>
      <pubDate>Fri, 22 May 2026 16:14:00 GMT</pubDate>
      <description>Changes to the Composition of Guerbet’s Board of Directors _________________________________________________________________ Appointment of Mr. Antoine Fady as an independent director and Chairman of the Board of DirectorsAppointment of three new directors representing the majority shareholder: Vincent Dagommer, Olivier Guerbet, and Emmanuelle Louvet _______________________________________________________________________________ Villepinte, May 22, 2026 Guerbet (FR0000032526 GBT), a global speci</description>
    </item>
    <item>
      <title>GUERBET : Change in Guerbet’s Board of Directors.</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-change-in-guerbets-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-change-in-guerbets-board-of-directors</guid>
      <pubDate>Wed, 11 Mar 2026 16:45:00 GMT</pubDate>
      <description>Change in Guerbet’s Board of Directors Villepinte, March 11th, 2026: Guerbet (FR0000032526 GBT), a global leader in contrast agents and solutions for medical imaging, today announced, at its Board of Directors’ meeting, the appointment of Mr. Antoine Fady as “censeur” (non-voting director) effective immediately. The appointment of Mr. Antoine Fady as a Director will be submitted for approval at the next Shareholders’ Meeting. Following this Shareholders’ Meeting, it will be proposed that the Boa</description>
    </item>
    <item>
      <title>Guerbet : 2025 revenue.</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-2025-revenue-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-2025-revenue-1</guid>
      <pubDate>Thu, 05 Feb 2026 16:45:00 GMT</pubDate>
      <description>2025 revenue Full-year revenue: €786.4 million, down 3.5% at CER1 and on a like-for-like basis2, largely due to the fall in business in FranceA decline in Q4 of 5.6% at CER and on a like-for-like basis, linked to the situation at the Raleigh site in the United States.2025: confirmation of the forecast range for restated EBITDA3 (between 10.5% and 12%) and an upward revision of the Free cash flow target, now expected to be positive2026: the situation at the Raleigh site is expected to impact reve</description>
    </item>
    <item>
      <title>Guerbet: Karim Boussebaa appointed Chief Executive Officer</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-karim-boussebaa-appointed-chief-executive-officer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-karim-boussebaa-appointed-chief-executive-officer-1</guid>
      <pubDate>Wed, 28 Jan 2026 16:45:00 GMT</pubDate>
      <description>Karim Boussebaa Appointed Chief Executive Officer of Guerbet Villepinte, January 28, 2026: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment of Mr. Karim Boussebaa as Chief Executive Officer of the Group. Meeting today, Guerbet’s Board of Directors, following the recommendation of the Nominations and Compensation Committee, has decided to appoint Mr. Karim Boussebaa as Chief Executive Officer. This appointment will tak</description>
    </item>
    <item>
      <title>Guerbet: Appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-appointment-of-mr-francois-convenant-as-senior-vice-president-of-interventional-radiology-and-his-entry-into-the-executive-committee-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-appointment-of-mr-francois-convenant-as-senior-vice-president-of-interventional-radiology-and-his-entry-into-the-executive-committee-1</guid>
      <pubDate>Fri, 19 Dec 2025 07:45:00 GMT</pubDate>
      <description>Guerbet announces the appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee Villepinte, December 19, 2025: GUERBET (FR0000032526 GBT), a global player in medical imaging, announces the appointment of François Convenant as Senior Vice President of Interventional Radiology.In this role, he joins the Guerbet Group&apos;s Executive Committee (COMEX). This appointment marks an important milestone for Guerbet, confirming its le</description>
    </item>
    <item>
      <title>GUERBET : Adjustment of 2025 financial targets.</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-adjustment-of-2025-financial-targets-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-adjustment-of-2025-financial-targets-1</guid>
      <pubDate>Tue, 02 Dec 2025 16:45:00 GMT</pubDate>
      <description>Adjustment of 2025 financial targets Villepinte, 2 December 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to its financial targets for full-year 2025. Following an inspection by the U.S. Food and Drug Administration (FDA) during the first half of the year, the Guerbet Group developed and initiated the implementation of a compliance plan at its Raleigh site in the United States. This plan ha</description>
    </item>
    <item>
      <title>GUERBET : Financial agenda for 2026</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-financial-agenda-for-2026-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-financial-agenda-for-2026-1</guid>
      <pubDate>Wed, 19 Nov 2025 12:47:00 GMT</pubDate>
      <description>Financial agenda for 2026 Villepinte, November 19, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2026. Publications calendar 2025 ANNUAL REVENUE February 05, 2026, after trading 2025 ANNUAL RESULTS March 11, 2026, after trading 2026 1ST QUARTER REVENUE April 23, 2026, after trading ANNUAL SHAREHOLDERS’ MEETING May 22, 2026 2026 2ND QUARTER REVENUE July 23, 2026, after trading 2026 FIRST HALF RESU</description>
    </item>
    <item>
      <title>Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-revenue-at-september-30-2025-return-to-growth-in-q3-2025-confirmation-of-all-financial-targets-for-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-revenue-at-september-30-2025-return-to-growth-in-q3-2025-confirmation-of-all-financial-targets-for-2025-1</guid>
      <pubDate>Thu, 23 Oct 2025 15:45:00 GMT</pubDate>
      <description>Revenue at September 30, 2025 Return to growth in Q3 2025 9-month revenue: €586.5 million, down 2.8% at CER1 and on a like-for-like basis2, largely due to the fall in activity in FranceAn increase in Q3 of 2.6% at CER and on a like-for-like basis, underpinned by the acceleration of EluciremTM sales and good momentum on Lipiodol® Confirmation of all financial targets for 2025 Villepinte, October 23, 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions</description>
    </item>
    <item>
      <title>Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on a like-for-like basis, mainly due to the decline in activity in France</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-h1-2025-results-h1-revenue-euro3878-million-down-54percent-at-cer-and-on-a-like-for-like-basis-mainly-due-to-the-decline-in-activity-in-france-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-h1-2025-results-h1-revenue-euro3878-million-down-54percent-at-cer-and-on-a-like-for-like-basis-mainly-due-to-the-decline-in-activity-in-france-1</guid>
      <pubDate>Wed, 24 Sep 2025 15:45:00 GMT</pubDate>
      <description>H1 2025 results Activity and profitability H1 revenue: €387.8 million, down 5.4% at CER1 and on a like-for-like basis2, mainly due to the decline in activity in FranceRestated EBITDA margin3 came out at 12.9%, compared with 15.4% a year earlier 2025 financial targets Revenue: slight decrease of approximately 1% at CER and on a like-for-like basisRestated EBITDA margin: between 12% and 13% of revenueFree cash flow: slightly negative Villepinte, September 24, 2025, 5.45 p.m.: Guerbet (FR0000032526</description>
    </item>
    <item>
      <title>Guerbet : Change in General Management</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-change-in-general-management-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-change-in-general-management-1</guid>
      <pubDate>Mon, 22 Sep 2025 15:45:00 GMT</pubDate>
      <description>Change in General Management Villepinte France, September 22nd, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment of Mr. Jérôme Estampes as interim Chief Executive Officer.Jérôme Estampes replaces Mr. David Hale, who is leaving the Group to pursue new projects. The Board of Directors thanks him for his work since joining Guerbet in February 2018, initially as Chief Commercial Officer and then as Chief Executive O</description>
    </item>
    <item>
      <title>Guerbet : Adjustment of 2025 full-year financial targets</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-adjustment-of-2025-full-year-financial-targets-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-adjustment-of-2025-full-year-financial-targets-1</guid>
      <pubDate>Mon, 15 Sep 2025 15:50:00 GMT</pubDate>
      <description>Adjustment of 2025 full-year financial targets Villepinte, 15 September 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to its financial targets for full-year 2025. Business activity in France continues to be impacted by supply reforms. In the United States, an unfavourable shift in the customer mix, with distributors representing a higher proportion of sales and ongoing pricing pressures has</description>
    </item>
    <item>
      <title>Guerbet : H1 2025 revenue</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-h1-2025-revenue-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-h1-2025-revenue-1</guid>
      <pubDate>Thu, 24 Jul 2025 15:45:00 GMT</pubDate>
      <description>H1 2025 revenue First-half activity H1 revenue of €387.8 million, down 5.4% at CER1 and like-for-like2 largely due to the fall in activity in FranceSales at CER and on a like-for-like basis increased in EMEA excluding France (+6.9%), were stable in the Americas (-0.3%) and fell in Asia (-7.3%)Double-digit growth is expected in H2, driven primarily by a more favorable comparison base and the normalization of activity in France Full-year targets confirmed Revenue growth of 3-5% at constant exchang</description>
    </item>
    <item>
      <title>Guerbet : Changes in the composition of the Guerbet board of directors.</title>
      <link>https://6ix.com/company/guerbet-sa/news/guerbet-changes-in-the-composition-of-the-guerbet-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/guerbet-sa/news/guerbet-changes-in-the-composition-of-the-guerbet-board-of-directors-1</guid>
      <pubDate>Mon, 26 May 2025 06:43:00 GMT</pubDate>
      <description>CHANGES IN THE COMPOSITION OF THE GUERBET BOARD OF DIRECTORS Reorganization of the Board of DirectorsDirectors&apos; terms of office reduced to 4 yearsAppointment of Ms Michèle Lesieur and Mr Eric Drapé as independent directorsReappointment of two directors _________________________________________________________________ Villepinte, May 23rd, 2025 Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, announces, following the Annual General Meeting of Ma</description>
    </item>
  </channel>
</rss>